Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03665831
Other study ID # CICP-2-00095
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 23, 2018
Est. completion date September 15, 2024

Study information

Verified date October 2023
Source Rotman Research Institute at Baycrest
Contact Amanda Rahmadian, BSc
Phone 416-785-2500
Email dtms@research.baycrest.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 diagnosed with mild to early-moderate Alzheimer's disease (AD) or mild cognitive impairment (MCI) and comorbid Major Depressive Disorder (MDD) who have been unable to tolerate or failed to respond to antidepressant medications. The coil was designed to stimulate deeper regions of the left dorsolateral prefrontal cortex (DLPFC). Based on prior research, the investigators propose that active stimulation with the H1 coil for 4 weeks may result in significant remission rates and will be tolerable and safe.


Description:

This study is an open-label trial to evaluate the safety and efficacy of H1-coil dTMS in treating depression in MCI and mild AD patients over 60 years of age who have not tolerated or failed to respond to antidepressant medications. 28 patients will be assigned to receive 4 consecutive weeks of daily active dTMS treatment. The long-term effects of treatment on emotional cognitive measures will be assessed at a 4-week follow-up visit (8 weeks from baseline). Symptom change and remission criteria will be assessed using the Montogmery-Asberg Depression Rating Scale (MADRS). Cognition will be assessed using a validated neuropsychological battery. We will also offer patients to receive 4 weeks of treatment using theta-burst TMS, which is a milder version of TMS.


Recruitment information / eligibility

Status Recruiting
Enrollment 28
Est. completion date September 15, 2024
Est. primary completion date August 15, 2024
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - meet DSM 5 criteria for Major or Mild Neurocognitive Disorder due to Alzheimer's disease with Clinical Dementia Rating Scale (CDR) score of at least 0.5 - have been diagnosed with DSM5 Major Depressive Disorder, with the current episode longer than 4 weeks but less than 5 years - did not respond to or did not tolerate antidepressant treatment - are willing to provide informed consent - are able to follow the treatment schedule - are stable on medications for 2 months and are not expected to change medication during the entire study period (if they are taking medications) - have a satisfactory safety screening questionnaire for TMS - have an informant/study partner who is able to complete study questionnaires regarding the participant Exclusion Criteria: - have a metal plate in their head, except in the mouth (such as an ear implant, implanted brain stimulators, aneurysm clips) - have known increased pressure or a history of increased pressure in their brain, which may increase their risk for having seizures - have a cardiac pacemaker - have an implanted medication pump - have a central venous line - have a significant heart disease or history of stroke - Modified Hachinski Score (MHIS) > 3 (to exclude those with significant vascular component to memory loss) - have a history of any psychotic disorder, bipolar disorder, eating disorder, obsessive compulsive disorder, post-traumatic stress disorder, or dementia other than AD - have a history of substance abuse in the last 6 months - have a history of stroke or other brain lesions - have a personal history of epilepsy - have a family history of epilepsy - are a pregnant or breast-feeding woman - are taking psychotropic medications including antidepressant medications, antipsychotics or mood stabilizing medications due to increased risk of seizure - are taking memantine - have a history of abnormal MRI of the brain - have significant hearing loss requiring use of hearing aids - have untreated hypo- or hyper-thyroidism

Study Design


Intervention

Device:
Brainsway H1-Coil Deep TMS System
Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.

Locations

Country Name City State
Canada Rotman Research Institute at Baycrest Toronto Ontario

Sponsors (3)

Lead Sponsor Collaborator
Rotman Research Institute at Baycrest Brainsway, Centre for Addiction and Mental Health

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) Therapeutic efficacy will be evaluated with the MADRS, a 10-item checklist. An effect size (Cohen's d) of 0.5 will be considered a minimally important effect size. 4 weeks
Secondary Remission Rates Compared Within Treatment Group Remission defined as MADRS < 10. 4 weeks
Secondary Response Rates Compared Within Treatment Group Response rate refers to the percentage of patients who responded to dTMS treatment and response is defined as a =50% reduction in MADRS score from baseline. 4 weeks
Secondary Change From Baseline on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) This 16-item questionnaire is designed to help assess the degree of enjoyment and satisfaction experienced during the past week. Administration time is approximately 5 minutes. 4 weeks
Secondary Change From Baseline on the Neuropsychological Battery Cognitive scores from the neuropsychological battery at baseline will be compared to 4 weeks post-intervention Cognitive domains tested include executive function, memory, language, attention, and intelligence. 4 weeks
Secondary Change in Functional Connectivity between PFC and Limbic Regions Subjects will have magnetic resonance imaging (MRI) scans of the brain. The change in functional connectivity between PFC and limbic regions, and within the default mode network, at rest is measured using resting state fMRI. 4 weeks
Secondary Change in Perfusion within Prefrontal Cortex (PFC) and Posterior Cingulate Cortex (PCC) Measured using Arterial Spin Labeling (ASL) fMRI scan. 4 weeks
Secondary Change in frontal theta power within the Anterior Cingulate Cortex (ACC) Measured with electroencephalography (EEG) and/or magnetoencephalography (MEG). 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A